Evidence map›Paper›PMID 42241516›Full record

ReviewCirculation research2026

Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis.

Giuliana G Repetti, E Dale Abel, Peter Tontonoz, Tamer Sallam

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Circulation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Giuliana G RepettiDepartment of Medicine (G.G.R., E.D.A., T.S.), David Geffen School of Medicine, University of California, Los Angeles, CA.ORCID 0000-0001-9172-6787
E Dale AbelDepartment of Medicine (G.G.R., E.D.A., T.S.), David Geffen School of Medicine, University of California, Los Angeles, CA.ORCID 0000-0001-5290-0738
Peter TontonozDepartment of Pathology and Lab Medicine (P.T.), David Geffen School of Medicine, University of California, Los Angeles, CA.ORCID 0000-0003-1259-0477
Tamer SallamDepartment of Medicine (G.G.R., E.D.A., T.S.), David Geffen School of Medicine, University of California, Los Angeles, CA.ORCID 0000-0001-7144-7393

Funding

RNA-binding proteins in atherosclerosisR01HL139549 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tamer Sallam · 2018 to 2026
$3.3M
Licensing LncRNAs in AtherosclerosisR01HL149766 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SALLAM, TAMER · 2021 to 2024
$2.5M
Long Non-coding RNAs in the Regulation of Adipogenesis and ObesityR01DK118086 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SALLAM, TAMER · 2018 to 2022
$1.9M
NHLBI NIH HHS R01 HL139549NHLBI NIH HHS R01 HL149766NIDDK NIH HHS R01 DK118086
6 · The paper itself

Abstract

Obesity and its cardiometabolic sequelae remain a public health challenge. GLP-1R (glucagon-like peptide-1 receptor) agonists have emerged as a transformative therapy to combat obesity. Although weight loss is a key part of how these drugs work, growing evidence suggests their cardioprotective effects may transcend the reduction in adiposity. In this review, we examine the weight-dependent and weight-independent mechanisms by which the GLP-1 axis affects cardiovascular risk, with a particular focus on lipoprotein metabolism and adipose tissue plasticity. We explore how GLP-1R agonists exert favorable effects on postprandial lipoprotein metabolism and examine potential mechanisms by which they influence adipose tissue function to enhance metabolic health. Finally, we discuss outstanding questions regarding incretin-based therapies and present a potential framework for expanding the use of GLP-1R agonists from weight loss agents into components of cardiovascular risk reduction strategies. Looking ahead, it is clear that the GLP-1 axis is a pleiotropic regulator of cardiometabolic health whose full therapeutic potential has not yet been realized.

Indexed as

Adipose TissueCardiovascular DiseasesGlucagon-Like Peptide 1LipoproteinsObesityAdiposityAnimalsGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHeart Disease Risk FactorsHumansIncretinsSignal TransductionWeight LossGLP1R protein, humanGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsIncretinsLipoproteinsadipose tissuecardiovascular diseasesincretinslipoproteinsobesityrisk factorsweight loss

Identifiers

PMID42241516
PMCPMC13339430

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.